BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016;29:772-784. [PMID: 27032689 DOI: 10.1038/modpathol.2016.55] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Cai L, Sun Y, Wang K, Guan W, Yue J, Li J, Wang R, Wang L. The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer. Front Oncol 2020;10:1269. [PMID: 32850385 DOI: 10.3389/fonc.2020.01269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Alsina M, Gullo I, Carneiro F. Intratumoral heterogeneity in gastric cancer: a new challenge to face. Ann Oncol. 2017;28:912-913. [PMID: 28368465 DOI: 10.1093/annonc/mdx134] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
3 Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, Arends MJ, Nagtegaal ID, Klimstra DS, Rugge M, Schirmacher P, Lazar AJ, Odze RD, Carneiro F, Fukayama M, Cree IA; WHO Classification of Tumours Editorial Board. Diagnosis of digestive system tumours. Int J Cancer 2021;148:1040-50. [PMID: 32674220 DOI: 10.1002/ijc.33210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Pikuła A, Kwietniewska M, Rawicz-Pruszyński K, Ciseł B, Skórzewska M, Gęca K, Franciszkiewicz-Pietrzak K, Kurylcio A, Mielko J, Polkowski WP. The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer. Semin Oncol 2020;47:127-37. [PMID: 32402473 DOI: 10.1053/j.seminoncol.2020.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ramos MFKP, Pereira MA, Amorim LC, de Mello ES, Faraj SF, Ribeiro U, Hoff PMG, Cecconello I, de Castria TB. Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype? J Surg Oncol 2020;121:804-13. [PMID: 31797380 DOI: 10.1002/jso.25792] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
6 Nasr R, Shamseddine A, Mukherji D, Nassar F, Temraz S. The Crosstalk between Microbiome and Immune Response in Gastric Cancer. Int J Mol Sci 2020;21:E6586. [PMID: 32916853 DOI: 10.3390/ijms21186586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Danilova N, Oleynikova N, Malkov P. 2019 WHO classification of gastric epithelial tumors, 5th edition. Arkh patol 2020;82:58. [DOI: 10.17116/patol20208204158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gonzalez RS, Messing S, Tu X, McMahon LA, Whitney-Miller CL. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.Hum Pathol. 2016;56:16-21. [PMID: 27342907 DOI: 10.1016/j.humpath.2016.06.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
9 Yu K, Ravoor A, Malats N, Pineda S, Sirota M. A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires. Front Immunol 2021;12:790119. [PMID: 35069569 DOI: 10.3389/fimmu.2021.790119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sanjeevaiah A, Cheedella N, Hester C, Porembka MR. Gastric Cancer: Recent Molecular Classification Advances, Racial Disparity, and Management Implications. J Oncol Pract 2018;14:217-24. [PMID: 29641950 DOI: 10.1200/JOP.17.00025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
11 Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int J Mol Sci 2019;20:E4781. [PMID: 31561483 DOI: 10.3390/ijms20194781] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 22.3] [Reference Citation Analysis]
12 Zhang X, Zhan D, Li Y, Wang H, Cheng C, Yao Y, Jia J. Glutathione Peroxidase 8 as a Prognostic Biomarker of Gastric Cancer: An Analysis of The Cancer Genome Atlas (TCGA) Data. Med Sci Monit 2020;26:e921775. [PMID: 32392186 DOI: 10.12659/MSM.921775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Nshizirungu JP, Bennis S, Mellouki I, Sekal M, Benajah DA, Lahmidani N, El Bouhaddouti H, Ibn Majdoub K, Ibrahimi SA, Celeiro SP, Viana-Pereira M, Munari FF, Ribeiro GG, Duval V, Santana I, Reis RM. Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients. Dis Markers 2021;2021:9980410. [PMID: 34367379 DOI: 10.1155/2021/9980410] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Glückstein MI, Dintner S, Arndt TT, Vlasenko D, Schenkirsch G, Agaimy A, Müller G, Märkl B, Grosser B. Comprehensive Immunohistochemical Study of the SWI/SNF Complex Expression Status in Gastric Cancer Reveals an Adverse Prognosis of SWI/SNF Deficiency in Genomically Stable Gastric Carcinomas. Cancers (Basel) 2021;13:3894. [PMID: 34359794 DOI: 10.3390/cancers13153894] [Reference Citation Analysis]
15 Zhang H, Wang Y, Wang Y, Wu D, Lin E, Xia Q. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer. Pathol Res Pract 2020;216:153229. [PMID: 33010699 DOI: 10.1016/j.prp.2020.153229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bösch F, Todorova R, Link H, Westphalen CB, Boeck S, Heinemann V, Werner J, Kirchner T, Angele MK, Neumann J. Molecular subtyping of gastric cancer with respect to the growth pattern of lymph-node metastases. J Cancer Res Clin Oncol 2019;145:2689-97. [PMID: 31541339 DOI: 10.1007/s00432-019-03029-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
17 He F, Fu Y, Sun Q, Geng P, Zheng Z, Pu X, Shi J, Fan X. Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: an exploration of histogenesis, molecular characteristics, and prognostic markers. Hum Pathol 2021;115:37-46. [PMID: 33636206 DOI: 10.1016/j.humpath.2021.02.003] [Reference Citation Analysis]
18 Tsai JH, Jeng YM, Chen KH, Lee CH, Yuan CT, Liau JY. An Integrative Morphomolecular Classification System of Gastric Carcinoma With Distinct Clinical Outcomes. Am J Surg Pathol 2020;44:1017-30. [PMID: 32568823 DOI: 10.1097/PAS.0000000000001521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Serra O, Galán M, Ginesta MM, Calvo M, Sala N, Salazar R. Comparison and applicability of molecular classifications for gastric cancer. Cancer Treat Rev 2019;77:29-34. [PMID: 31195213 DOI: 10.1016/j.ctrv.2019.05.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
20 Koh J, Lee KW, Nam SK, Seo AN, Kim JW, Kim JW, Park DJ, Kim HH, Kim WH, Lee HS. Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications. Oncologist 2019;24:e1321-30. [PMID: 31371521 DOI: 10.1634/theoncologist.2019-0058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
21 Wang Q, Liu G, Hu C. Molecular Classification of Gastric Adenocarcinoma. Gastroenterology Res. 2019;12:275-282. [PMID: 31803306 DOI: 10.14740/gr1187] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
22 Pretzsch E, Bösch F, Todorova R, Nieß H, Jacob S, Guba M, Kirchner T, Werner J, Klauschen F, Angele MK, Neumann J. Molecular subtyping of gastric cancer according to ACRG using immunohistochemistry – correlation with clinical parameters. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153797] [Reference Citation Analysis]
23 Danilova NV, Popov PV, Oleynikova NA, Malkov PG, Kharlova OA, Yusupova KI, Agapov MA. [Gastric adenocarcinoma arising in giant hyperplastic polyp]. Arkh Patol 2017;79:43-52. [PMID: 29265077 DOI: 10.17116/patol201779643-52] [Reference Citation Analysis]
24 Kim DH, Bae GE, Suh KS, Ryuman D, Song KS, Kim JS, Lee SI, Yeo MK. Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma. In Vivo 2020;34:3171-80. [PMID: 33144421 DOI: 10.21873/invivo.12152] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Pinto MP, Córdova-Delgado M, Retamal IN, Muñoz-Medel M, Bravo ML, Durán D, Villanueva F, Sanchez C, Acevedo F, Mondaca S, Koch É, Ibañez C, Galindo H, Madrid J, Nervi B, Peña J, Torres J, Owen GI, Corvalán AH, Armisén R, Garrido M. A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability. Cancers (Basel) 2020;12:E1863. [PMID: 32664343 DOI: 10.3390/cancers12071863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Birkman EM, Mansuri N, Kurki S, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén O. Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics.Virchows Arch. 2018;472:369-382. [PMID: 29046940 DOI: 10.1007/s00428-017-2240-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
27 Koh J, Nam SK, Roh H, Kim J, Lee BC, Kim JW, Ahn SH, Park DJ, Kim HH, Park KU, Chung JH, Kim WH, Lee HS. Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. Genes Chromosomes Cancer 2019;58:12-22. [PMID: 30239046 DOI: 10.1002/gcc.22683] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
28 Kim JY, Kim WG, Kwon CH, Park DY. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact. Gastric Cancer 2019;22:1164-75. [PMID: 31152268 DOI: 10.1007/s10120-019-00974-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
29 Wang Q, Shu X, Dong Y, Zhou J, Teng R, Shen J, Chen Y, Dong M, Zhang W, Huang Y, Xie S, Wei Q, Zhao W, Chen W, Yuan X, Qi X, Wang L. Tumor and serum gamma-glutamyl transpeptidase, new prognostic and molecular interpretation of an old biomarker in gastric cancer. Oncotarget. 2017;8:36171-36184. [PMID: 28404903 DOI: 10.18632/oncotarget.15609] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
30 Cartwright E, Athauda A, Chau I. Emerging precision therapies for gastric cancer. Expert Review of Precision Medicine and Drug Development 2020;5:299-311. [DOI: 10.1080/23808993.2020.1760089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Gullo I, Grillo F, Mastracci L, Vanoli A, Carneiro F, Saragoni L, Limarzi F, Ferro J, Parente P, Fassan M. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. Pathologica 2020;112:166-85. [PMID: 33179620 DOI: 10.32074/1591-951X-166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Grosser B, Glückstein MI, Dhillon C, Schiele S, Dintner S, VanSchoiack A, Kroeppler D, Martin B, Probst A, Vlasenko D, Schenkirsch G, Märkl B. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes. J Pathol 2021. [PMID: 34580877 DOI: 10.1002/path.5810] [Reference Citation Analysis]
33 Kwak Y, Seo AN, Lee HE, Lee HS. Tumor immune response and immunotherapy in gastric cancer. J Pathol Transl Med 2020;54:20-33. [PMID: 31674166 DOI: 10.4132/jptm.2019.10.08] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
34 Setia N, Ahn S, Han HS, Park DY, Lauwers GY. Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma. Hum Pathol 2019;94:64-70. [PMID: 31676362 DOI: 10.1016/j.humpath.2019.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kataoka I, Funata S, Nagahama K, Isogaya K, Takeuchi H, Abe N, Shibahara J. DNMT3A overexpression is associated with aggressive behavior and enteroblastic differentiation of gastric adenocarcinoma. Ann Diagn Pathol 2020;44:151456. [PMID: 31862523 DOI: 10.1016/j.anndiagpath.2019.151456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Molina-Castro S, Pereira-Marques J, Figueiredo C, Machado JC, Varon C. Gastric cancer: Basic aspects. Helicobacter 2017;22 Suppl 1. [PMID: 28891129 DOI: 10.1111/hel.12412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
37 Garcia-Pelaez J, Barbosa-Matos R, Gullo I, Carneiro F, Oliveira C. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Mol Oncol 2021. [PMID: 33724653 DOI: 10.1002/1878-0261.12948] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Valentini AM, Di Pinto F, Coletta S, Guerra V, Armentano R, Caruso ML. Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. Oncol Lett 2019;18:1775-85. [PMID: 31423245 DOI: 10.3892/ol.2019.10513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Gonzalez RS, Cates JMM, Revetta F, McMahon LA, Washington K. Gastric Carcinomas With Lymphoid Stroma: Categorization and Comparison With Solid-Type Colonic Carcinomas. Am J Clin Pathol 2017;148:477-84. [PMID: 29126141 DOI: 10.1093/ajcp/aqx096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
40 Ramos MFKP, Pereira MA, de Mello ES, Cirqueira CDS, Zilberstein B, Alves VAF, Ribeiro-Junior U, Cecconello I. Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery. World J Clin Oncol 2021;12:688-701. [PMID: 34513602 DOI: 10.5306/wjco.v12.i8.688] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Han WH, Eom BW, Yoon HM, Kim YW, Kook MC, Ryu KW. The Different Clinicopathological Features of Remnant Gastric Cancer Depending on Initial Disease of Partial Gastrectomy. Cancers (Basel) 2020;12:E2847. [PMID: 33023082 DOI: 10.3390/cancers12102847] [Reference Citation Analysis]
42 Sun Y, Yu W, Guan W, Cai L, Qiao M, Zheng L, Jiang R, Wang R, Wang L. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. Cancer Manag Res 2019;11:6397-410. [PMID: 31372044 DOI: 10.2147/CMAR.S206189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
43 Xue LY, Qin XM, Liu Y, Liang J, Lin H, Xue XM, Zou SM, Zhang MY, Zhang BH, Hui ZG, Zhao ZT, Ren LQ, Zhang YM, Liu XY, Yuan YL, Ying JM, Gao SG, Song YM, Wang GQ, Dawsey SM, Lu N. Clinicopathological parameters predicting recurrence of pT1N0 esophageal squamous cell carcinoma. World J Gastroenterol 2018; 24(45): 5154-5166 [PMID: 30568392 DOI: 10.3748/wjg.v24.i45.5154] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
44 Daun T, Nienhold R, Paasinen-Sohns A, Frank A, Sachs M, Zlobec I, Cathomas G. Combined Simplified Molecular Classification of Gastric Adenocarcinoma, Enhanced by Lymph Node Status: An Integrative Approach. Cancers (Basel) 2021;13:3722. [PMID: 34359622 DOI: 10.3390/cancers13153722] [Reference Citation Analysis]
45 Gullo I, Oliveira P, Athelogou M, Gonçalves G, Pinto ML, Carvalho J, Valente A, Pinheiro H, Andrade S, Almeida GM, Huss R, Das K, Tan P, Machado JC, Oliveira C, Carneiro F. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer 2019;22:77-90. [DOI: 10.1007/s10120-018-0836-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
46 Du WB, Lin CH, Chen WB. High expression of APC is an unfavorable prognostic biomarker in T4 gastric cancer patients. World J Gastroenterol 2019; 25(31): 4452-4467 [PMID: 31496624 DOI: 10.3748/wjg.v25.i31.4452] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
47 Zhao C, Feng Z, He H, Zang D, Du H, Huang H, Du Y, He J, Zhou Y, Nie Y. Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray. PLoS One 2020;15:e0238836. [PMID: 33095797 DOI: 10.1371/journal.pone.0238836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Cisło M, Filip AA, Arnold Offerhaus GJ, Ciseł B, Rawicz-Pruszyński K, Skierucha M, Polkowski WP. Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. Oncotarget 2018;9:19427-42. [PMID: 29721214 DOI: 10.18632/oncotarget.24827] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
49 Wang X, Che K, Shi T, Liu Q, Xu X, Wu H, Yu L, Liu B, Wei J. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer. J Cancer Res Clin Oncol 2022. [PMID: 35294647 DOI: 10.1007/s00432-022-03971-w] [Reference Citation Analysis]
50 Ahn S, Lee SJ, Kim Y, Kim A, Shin N, Choi KU, Lee CH, Huh GY, Kim KM, Setia N, Lauwers GY, Park DY. High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. Am J Surg Pathol. 2017;41:106-115. [PMID: 27819872 DOI: 10.1097/pas.0000000000000756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 9.2] [Reference Citation Analysis]
51 Itami H, Morita K, Nakai T, Uchiyama T, Sugimoto S, Sasaki S, Matsuoka M, Myojin T, Nitta Y, Okabe F, Fujii T, Hatakeyama K, Mitoro A, Sho M, Ohbayashi C. Gastritis cystica profunda is associated with aberrant p53 and Epstein-Barr virus in gastric cancer: A clinicopathological, immunohistochemical and in situ hybridization study. Pathol Int 2021;71:42-50. [PMID: 33084164 DOI: 10.1111/pin.13039] [Reference Citation Analysis]
52 Danilova NV, Mikhailov IA, Oleynikova NA, Malkov PG. [E-cadherin expression in tumor emboli in gastric cancer]. Arkh Patol 2021;83:11-9. [PMID: 34041891 DOI: 10.17116/patol20218303111] [Reference Citation Analysis]
53 Seeneevassen L, Bessède E, Mégraud F, Lehours P, Dubus P, Varon C. Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies. Int J Mol Sci 2021;22:3418. [PMID: 33810350 DOI: 10.3390/ijms22073418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
54 Bao B, Zheng C, Yang B, Jin Y, Hou K, Li Z, Zheng X, Yu S, Zhang X, Fan Y, Qu X, Liu Y, Che X. Identification of Subtype-Specific Three-Gene Signature for Prognostic Prediction in Diffuse Type Gastric Cancer. Front Oncol. 2019;9:1243. [PMID: 31803620 DOI: 10.3389/fonc.2019.01243] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
55 Hewitt LC, Inam IZ, Saito Y, Yoshikawa T, Quaas A, Hoelscher A, Bollschweiler E, Fazzi GE, Melotte V, Langley RE, Nankivell M, Cunningham D, Allum W, Hutchins GG, Grabsch HI. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. Eur J Cancer 2018;94:104-14. [PMID: 29550565 DOI: 10.1016/j.ejca.2018.02.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
56 Arai H, Nakajima TE. Recent Developments of Systemic Chemotherapy for Gastric Cancer. Cancers (Basel) 2020;12:E1100. [PMID: 32354119 DOI: 10.3390/cancers12051100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
57 Klein S, Duda DG. Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. Cancers (Basel) 2021;13:4919. [PMID: 34638408 DOI: 10.3390/cancers13194919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Hwang HJ, Nam SK, Park H, Park Y, Koh J, Na HY, Kwak Y, Kim WH, Lee HS. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer. J Pathol Transl Med 2020;54:378-86. [PMID: 32601264 DOI: 10.4132/jptm.2020.06.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
59 Xue L, Li W, Fan X, Zhao Z, Zhou W, Feng Z, Liu L, Lin H, Li L, Xue X, Huang X, Huang P, Guo J, Du P, Lu N, Li L, Zhan Q, Song Y. Identification of second primary tumors from lung metastases in patients with esophageal squamous cell carcinoma using whole-exome sequencing. Theranostics 2020;10:10606-18. [PMID: 32929369 DOI: 10.7150/thno.45311] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Pereira MA, Ramos MFKP, Faraj SF, Dias AR, Yagi OK, Zilberstein B, Cecconello I, Alves VAF, de Mello ES, Ribeiro U Jr. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J Surg Oncol 2018;117:829-39. [PMID: 29534305 DOI: 10.1002/jso.25022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
61 Pereira MA, Ramos MFKP, Dias AR, Ribeiro R, Cardili L, Zilberstein B, Cecconello I, Ribeiro U Jr, de Mello ES, de Castria TB. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. Virchows Arch 2021;478:1039-48. [PMID: 33098489 DOI: 10.1007/s00428-020-02956-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
62 Koh J, Ock CY, Kim JW, Nam SK, Kwak Y, Yun S, Ahn SH, Park DJ, Kim HH, Kim WH, Lee HS. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget 2017;8:26356-67. [PMID: 28412752 DOI: 10.18632/oncotarget.15465] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
63 Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F, Sun W. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. Am J Surg Pathol. 2016;40:1496-1506. [PMID: 27465786 DOI: 10.1097/pas.0000000000000698] [Cited by in Crossref: 83] [Cited by in F6Publishing: 59] [Article Influence: 16.6] [Reference Citation Analysis]
64 Zhao X, Xia X, Wang X, Bai M, Zhan D, Shu K. Deep Learning-Based Protein Features Predict Overall Survival and Chemotherapy Benefit in Gastric Cancer. Front Oncol 2022;12:847706. [DOI: 10.3389/fonc.2022.847706] [Reference Citation Analysis]
65 Zeng Y, Jin RU. Molecular Pathogenesis, Targeted Therapies, and Future Perspectives for Gastric Cancer. Semin Cancer Biol 2021:S1044-579X(21)00297-2. [PMID: 34933124 DOI: 10.1016/j.semcancer.2021.12.004] [Reference Citation Analysis]
66 Sitarz R, Polkowski WP, Maciejewski R, Offerhaus GJA. Risk of peritoneal dissemination in stomach cancer. Current Issues in Pharmacy and Medical Sciences 2017;30:184-6. [DOI: 10.1515/cipms-2017-0034] [Reference Citation Analysis]
67 Pereira MA, Ramos MFKP, Dias AR, Cardili L, Ribeiro RRE, de Castria TB, Zilberstein B, Nahas SC, Ribeiro U Jr, de Mello ES. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients. Med Sci (Basel) 2021;10:4. [PMID: 35076580 DOI: 10.3390/medsci10010004] [Reference Citation Analysis]
68 Maleki SS, Röcken C. Chromosomal Instability in Gastric Cancer Biology. Neoplasia 2017;19:412-20. [PMID: 28431273 DOI: 10.1016/j.neo.2017.02.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
69 Kohlruss M, Reiche M, Jesinghaus M, Grosser B, Slotta-Huspenina J, Hapfelmeier A, Bauer L, Novotny A, Weichert W, Keller G. A microsatellite based multiplex PCR method for the detection of chromosomal instability in gastric cancer. Sci Rep 2018;8:12551. [PMID: 30135548 DOI: 10.1038/s41598-018-30971-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
70 Silva ANS, Saito Y, Yoshikawa T, Oshima T, Hayden JD, Oosting J, Earle S, Hewitt LC, Slaney HL, Wright A, Inam I, Langley RE, Allum W, Nankivell MG, Hutchins G, Cunningham D, Grabsch HI. Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma. Br J Surg 2022:znab460. [PMID: 35179206 DOI: 10.1093/bjs/znab460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Huang SC, Ng KF, Yeh TS, Cheng CT, Lin JS, Liu YJ, Chuang HC, Chen TC. Subtraction of Epstein-Barr virus and microsatellite instability genotypes from the Lauren histotypes: Combined molecular and histologic subtyping with clinicopathological and prognostic significance validated in a cohort of 1,248 cases.Int J Cancer. 2019;145:3218-3230. [PMID: 30771224 DOI: 10.1002/ijc.32215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
72 Yoon JY, Sy K, Brezden-Masley C, Streutker CJ. Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study. PLoS One 2019;14:e0224812. [PMID: 31790410 DOI: 10.1371/journal.pone.0224812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
73 Schoop I, Maleki SS, Behrens HM, Krüger S, Haag J, Röcken C. p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort. Hum Pathol 2020;105:53-66. [PMID: 32971129 DOI: 10.1016/j.humpath.2020.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
74 Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, Nappo F, Businello G, Sbaraglia M, Bergamo F, Spolverato G, Pucciarelli S, Merigliano S, Pilati P, Cavallin F, Realdon S, Farinati F, Dei Tos AP, Zagonel V, Lonardi S, Loupakis F, Fassan M. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J Pers Med 2021;11:1095. [PMID: 34834447 DOI: 10.3390/jpm11111095] [Reference Citation Analysis]
75 Jeon J, Cheong JH. Clinical Implementation of Precision Medicine in Gastric Cancer. J Gastric Cancer 2019;19:235-53. [PMID: 31598369 DOI: 10.5230/jgc.2019.19.e25] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
76 Chen Y, Zhou Q, Wang H, Zhuo W, Ding Y, Lu J, Wu G, Xu N, Teng L. Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers. Cancers (Basel) 2020;12:E2236. [PMID: 32785164 DOI: 10.3390/cancers12082236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
77 Dislich B, Blaser N, Berger MD, Gloor B, Langer R. Preservation of Epstein-Barr virus status and mismatch repair protein status along the metastatic course of gastric cancer. Histopathology 2020;76:740-7. [PMID: 31898331 DOI: 10.1111/his.14059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
78 Wen KW, Rabinovitch PS, Huang D, Mattis AN, Lauwers GY, Choi W. Use of DNA flow cytometry in the diagnosis, risk stratification, and management of gastric epithelial dysplasia. Mod Pathol 2018;31:1578-87. [DOI: 10.1038/s41379-018-0062-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]